Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab vs Standard Chemotherapy in Advanced Pre-treated Malignant Pleural Mesothelioma
NCT02991482Phase 3Completed
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Sep 2017
- Primary completion
- Feb 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 3 trial of pembrolizumab in malignant pleural mesothelioma (MPM), sponsored by ETOP IBCSG Partners Foundation. Started Sep 2017; status: completed.
02
Drugs
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT02991482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02991482.